Creo Medical Group PLC Director/PDMR Shareholding (4305Z)
August 31 2018 - 5:30AM
UK Regulatory
TIDMCREO
RNS Number : 4305Z
Creo Medical Group PLC
31 August 2018
31 August 2018
Creo Medical Group plc
(the "Company")
Director/PDMR Dealing
Further to the completion of the Placing which occurred
yesterday, and as detailed in the Company's announcement dated 13
July 2018, Craig Gulliford, Chief Executive Officer, and Chris
Hancock, Chief Technology Officer, each sold 480,000 ordinary
shares of 0.1 pence each in the capital of the Company ("Ordinary
Shares") on 30 August 2018 at the Placing Price of GBP1.25 per
Ordinary Share.
Following these trades, Mr Gulliford holds 609,886 Ordinary
Shares representing approximately 0.51% of the Company's enlarged
issued share capital and Mr Hancock holds 4,400,046 Ordinary
Shares, representing approximately 3.67% of the Company's enlarged
issued share capital.
Capitalised terms used, but not defined, in this announcement
shall have the same meaning as set out in the Circular.
The Company makes the following disclosures in accordance with
article 19(3) of the Market Abuse Regulation:
1 Details of the person discharging managerial responsibilities / person closely associated
a) Name Craig Gulliford
------------------------------------------------------------ -----------------------------------
2 Reason for the notification
-------------------------------------------------------------------------------------------------
a) Position/status Chief Executive Officer
------------------------------------------------------------ -----------------------------------
b) Initial notification /Amendment Initial
------------------------------------------------------------ -----------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
-------------------------------------------------------------------------------------------------
a) Name Creo Medical Group plc
------------------------------------------------------------ -----------------------------------
b) LEI 213800H188ZDCWWXFA21
------------------------------------------------------------ -----------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
-------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of instrument Ordinary shares of 0.1 pence each
Identification code
GB00BZ1BLL44
------------------------------------------------------------ -----------------------------------
b) Nature of the transaction Sale of Ordinary Shares
------------------------------------------------------------ -----------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
GBP1.25 480,000
----------
------------------------------------------------------------ -----------------------------------
d) Aggregated information n/a - single transaction
- Aggregated volume
- Price
------------------------------------------------------------ -----------------------------------
e) Date of the transaction 30 August 2018
------------------------------------------------------------ -----------------------------------
f) Place of the transaction London Stock Exchange
------------------------------------------------------------ -----------------------------------
1 Details of the person discharging managerial responsibilities / person closely associated
a) Name Chris Hancock
------------------------------------------------------------ -----------------------------------
2 Reason for the notification
-------------------------------------------------------------------------------------------------
a) Position/status Chief Technology Officer
------------------------------------------------------------ -----------------------------------
b) Initial notification /Amendment Initial
------------------------------------------------------------ -----------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
-------------------------------------------------------------------------------------------------
a) Name Creo Medical Group plc
------------------------------------------------------------ -----------------------------------
b) LEI 213800H188ZDCWWXFA21
------------------------------------------------------------ -----------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
-------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of instrument Ordinary shares of 0.1 pence each
Identification code
GB00BZ1BLL44
------------------------------------------------------------ -----------------------------------
b) Nature of the transaction Sale of Ordinary Shares
------------------------------------------------------------ -----------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
GBP1.25 480,000
----------
------------------------------------------------------------ -----------------------------------
d) Aggregated information n/a - single transaction
- Aggregated volume
- Price
------------------------------------------------------------ -----------------------------------
e) Date of the transaction 30 August 2018
------------------------------------------------------------ -----------------------------------
f) Place of the transaction London Stock Exchange
------------------------------------------------------------ -----------------------------------
Contacts
Creo Medical: Cenkos: FTI Consulting:
Richard Rees Mark Connelly (NOMAD) Brett Pollard / Mo Noonan
+44 (0)129 160 6005 Michael Johnson / Russell Kerr (Sales) +44 (0)203 727 1000
richard.rees@creomedical.com +44 (0)207 397 8900 creo@fticonsulting.com
About Creo Medical
Creo Medical, founded in 2003, is a medical device company
focused on the development and commercialisation of minimally
invasive surgical devices, by bringing advanced energy to
endoscopy. The Company's mission is to improve patient outcomes by
applying microwave and radiowave energy to surgical endoscopy. Creo
has developed CROMA, an electrosurgical platform that combines
bipolar radiofrequency for precise localised cutting and microwave
for controlled coagulation. This technology provides physicians
with flexible, accurate and controlled surgical solutions.
The Company's strategy is to bring the CROMA surgical system to
market through a suite of medical instruments which the Company has
designed, initially for GI therapeutic endoscopy, an area with high
unmet needs. The CROMA system will be developed further for
bronchoscopy and laparoscopy procedures. The Company believes its
technology can impact the landscape of surgery and endoscopy by
providing safer, less-invasive and more cost-efficient option of
treatment.
For more information about Creo Medical please see our website,
www.creomedical.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHLLFFITTILVIT
(END) Dow Jones Newswires
August 31, 2018 06:30 ET (10:30 GMT)
Creo Medical (LSE:CREO)
Historical Stock Chart
From Apr 2024 to May 2024
Creo Medical (LSE:CREO)
Historical Stock Chart
From May 2023 to May 2024
